Clinical trial · Interventional
Local Inflammation in Arrhythmogenic Right Ventricular Cardiomyopathy
NCT05209776CI-TRIAL-00113211LI-ARVCrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The understanding of ARVC pathophysiology remains incomplete. Several clues indicate that disease progression is mediated through inflammation. The present study aim to document the feasibility of detecting the potential presence of intracardiac local inflammatory components in patients with ARVC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Arrhythmogenic Right Ventricular Dysplasia | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immunological assessment carried out on intracardiac material | Biological | — | UNRESOLVED |
| Peripheral immunological assessment on venous blood | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Patients
- description
- Carrier of a definite diagnosis of arrhythmogenic dysplasia of the right ventricle in line with the criteria of the Task Force 2010 (see Appendices), admitted for an electrical mapping of the right ventricle
- interventionNames
- Biological: Peripheral immunological assessment on venous blood
- Biological: Immunological assessment carried out on intracardiac material
- type
- EXPERIMENTAL
- label
- Control case
- description
- Without heart disease, admitted for a Kent bundle ablation or endocavity procedure / Wolff-Parkinson-White syndrome or common flutter (in subjects in whom the same irrigated material will be used and for whom echocardiography will have excluded associated heart disease).
- interventionNames
- Biological: Peripheral immunological assessment on venous blood
- Biological: Immunological assessment carried out on intracardiac material
Primary outcomes (6)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * For cases: * Arrhythmogenic right ventricular dysplasia diagnosed (according to 2010 Task Force Criteria) * Admitted for right ventricle electrophysiologic mapping * For controls \* Admitted for ablation procedures (accessory pathway, atrial flutter) on otherwise healthy hearts. Exclusion Criteria: * Diagnostic of systemic chronic inflammatory disease * Presence of possible or proven cardiac involvement of an inflammatory disease, an acute or chronic infectious disease. * Taking immunosuppressant or immunomodulating medications
References
Publications (0)
Data not yet available
No reference posted for this study.